Immunic Inc Stock Price, News & Analysis

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, will participate in two key scientific conferences in October 2020. From October 6-7, CEO Daniel Vitt will present at BioNJ's 10th Annual BioPartnering Conference, with a presentation available online. Additionally, from October 26-29, the management team will host one-on-one meetings at BIO-Europe® Digital 2020. Immunic is advancing treatments for chronic inflammatory diseases, including multiple sclerosis and ulcerative colitis, and recently reported positive phase 2 trial results for its lead product, IMU-838.

Immunic, Inc. (Nasdaq: IMUX) announced positive results from the interim safety analysis of its phase 2 CALVID-1 trial for IMU-838, a selective oral DHODH inhibitor, in moderate COVID-19 patients. The Independent Data Monitoring Committee found no safety concerns, recommending that the trial proceed without changes. Currently, 110 patients have been enrolled out of the targeted 230. Immunic plans to report unblinded interim efficacy and biomarker data later this year, potentially leading to a phase 3 trial expansion.

Immunic, Inc. (Nasdaq: IMUX) announced the release of full unblinded clinical data from the Phase 2 EMPhASIS trial for IMU-838, targeting relapsing-remitting multiple sclerosis (RRMS). The trial met primary and secondary endpoints with significant reductions in MRI lesions: 62% for 45mg and 70% for 30mg doses versus placebo. IMU-838 demonstrated a favorable safety profile, with adverse events similar to placebo. The results indicate potential for IMU-838 as a leading oral treatment for RRMS, with further discussions planned for a Phase 3 trial.

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, announced its participation in key scientific and investor conferences in September 2020. From September 11-13, Immunic will present data from the phase 2 EMPhASIS trial of IMU-838 at the MSVirtual2020, showcasing results in patients with relapsing-remitting multiple sclerosis. Additionally, on September 23, CEO Daniel Vitt will engage in a fireside chat during the Jefferies Next Generation IBD Therapeutics Virtual Summit. For more information, visit ir.imux.com/events-and-presentations.

Immunic, Inc. (Nasdaq: IMUX) has initiated its phase 1 clinical program for IMU-856, a novel oral therapy aimed at restoring intestinal barrier function and targeting gastrointestinal diseases. The first healthy volunteer has been dosed, marking progress toward evaluating the drug's potential as a treatment option for conditions like IBS-D, ulcerative colitis, and Crohn's disease. The program is designed to assess safety and pharmacokinetics in healthy subjects before moving to patients. This development follows promising preclinical data and a license agreement with Daiichi Sankyo.

Immunic, Inc. (Nasdaq: IMUX) has successfully closed a public offering of 5,750,000 shares of common stock at $18.00 per share, raising approximately $103.5 million. This includes the full exercise of the underwriters' option to purchase an additional 750,000 shares. The proceeds will be utilized to advance clinical development for lead candidates IMU-838, IMU-935, and IMU-856, particularly for a potential Phase 3 trial of IMU-838 in relapsing-remitting multiple sclerosis. The offering was managed by SVB Leerink, with Wedbush PacGrow and Ladenburg Thalmann acting as co-managers.

Immunic, Inc. (Nasdaq: IMUX) has announced a public offering of 5,000,000 shares at $18.00 each, aiming to raise approximately $90.0 million. The offering, subject to customary closing conditions, is expected to close on August 7, 2020. The net proceeds will fund the clinical development of key candidates, including IMU-838 for multiple sclerosis. The company has also granted underwriters a 30-day option to purchase an additional 750,000 shares. This offering follows a shelf registration statement with the SEC.

Immunic, Inc. (Nasdaq: IMUX) has announced plans to offer 5 million shares of common stock in an underwritten public offering, with underwriters granted an option for 750,000 additional shares. This is part of their ongoing efforts to support the development of selective oral immunology therapies for chronic inflammatory diseases. The offering's completion is dependent on market conditions. Joint bookrunning managers for this offering are SVB Leerink and Piper Sandler, with additional involvement from Wedbush PacGrow and Ladenburg Thalmann.

Immunic, Inc. (Nasdaq: IMUX) announced it will report its financial results for Q2 2020 on August 3, 2020, prior to U.S. market opening. The company is focused on oral therapies for chronic inflammatory and autoimmune diseases, including its lead product IMU-838, currently in phase 2 trials for multiple conditions, including COVID-19 and relapsing-remitting multiple sclerosis. A public conference call will follow the results announcement at 8:30 a.m. ET on the same day. Investors can access a live webcast or replay on Immunic's website.